Funding Details
- Awarder
- Inbox
- Date Award
- May 16, 2025
- Vertical
- Biotech
- Funding URL
- View Funding Page
Company Info
- Traction
- The company has secured CHF 1M from the UZH Life Sciences Fund to advance its lead candidate through preclinical development.
- Founders
- Michal Shoshan
- Company Description
- metaLead Therapeutics is developing a new class of metal-binding drugs aimed at overcoming the shortcomings of existing chelation therapies, focusing on Wilson disease, a genetic disorder that leads to toxic copper accumulation.
- Market
- Wilson disease treatment
- Location
-
Zurich,
Switzerland
Links